NEW YORK (TheStreet) -- Shares of Pfizer (PFE) are lower by roughly 1.2% in early Monday trading, following its drug acquisition deal with Merck (MRK) . 

Merck -- which is higher by more than 0.5% --agreed to sell its immunotherapy drug for $850 million. However, the deal could be worth up to $2 billion if the drug clears certain regulatory hurdles and sales goals. 

PFE Chart
Pfizer PFE data by YCharts

On CNBC's "Cramer's Mad Dash" segment, Cramer, the co-manager of the Action Alerts PLUS portfolio, reasoned that Pfizer may no longer be interested in acquiring AstraZeneca (AZN) .

Previously, Pfizer was interested in the company for its oncology franchise. But with its latest acquisition from Merck, there no longer appears to be a catalyst behind a Pfizer-AstraZeneca deal, he said. 

Cramer also pointed out AbbVie's (ABBV) recent share price performance. The stock has been one of the best performing biotech stocks since the planned acquisition of Shire (SHPG) surprisingly fell through

Maybe it's time that AbbVie gets some credit for its "fantastic" hepatitis C franchise, he concluded. 

-- Written by Bret Kenwell

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS was long ABBV and MRK.

More from Opinion

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider